There is a lot of money hiding out in a few sub-groups, including banks, biotech, and Internet names like Google and Facebook.» Read More
Futures were poised for a modestly higher open on the strength of more earnings surprises from some of Wall Street's leading companies.
Following are the day’s biggest winners and losers. Find out why shares of Nike and Huntington Bancshares popped while Biogen and Saks dropped.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
With new data showing that consumers are unlikely to help spark growth anytime soon, can the market sustain its recent gains?
Biotech companies continued their rally today, with the biotech index up more than 35 percent in the last three months. Eric Schmidt, biotech analyst at Cowen, and Joel Sendek, managing director and biotech analyst at Lazard Capital Markets, explained the force behind the comeback and the best stock plays for investors right now.
Stocks continued to struggle on Friday. Could this be the beginning of a real market correction? Mike Rubino, president of Rubino Financial, and Paul Schatz, president of Heritage Capital, discussed how investors should position their portfolios for the end of the third quarter.
Big money managers can instill confidence in individual stocks and you may be able to profit off their moves. Karen Finerman breaks down the holdings of the major money managers.
Opposition to the Obama administration's health care plan had a new voice Monday, as the U.S. Chamber of Commerce launched a critical ad campaign suggesting alternatives. But John Sullivan of Leerink Swann says this is a great time to buy health stocks.
A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?
Carl Icahn and all of the Elanians should be happy. Biogen Idec today reported encouraging trends regarding its all-important multiple sclerosis drug Tysabri.
Brent Wilsey, president of Wilsey Asset Management, and Rod Smyth, chief investment strategist of Riverfront Investment, shared their economic outlooks and advised investors how to seek maximum profits.
Investors are placing their bets ahead of a string of pharma earnings due both this week and next. What must you know?
Earnings season should provide a fresh view of the U.S. economy and may shake the stock market out of its summer doldrums.
Douglas Roberts, founder and chief investment strategist at ChannelCapitalResearch.com and Mike Williams, founder and managing partner at Genesis Asset Management shared their opposing market views and advised investors on where they should put their money.
Shares of Human Genome Sciences are up on the day Thursday and bringing in option traders. HGSI is up more than 4 percent to $3.15 in early afternoon trading, well off the $3.44 high of the day that was reached just after the open.
In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.
The cost of drugs was a hot topic at ASCO this year, especially with the release of the big test results combining two very expensive treatments for lung cancer. The study showed using Avastin from Roche and Genentech and a pill, Tarceva, from OSI Pharmaceuticals, Roche and Genentech slowed down progression of the disease by a little more than a month.
I'm juggling the Amylin Pharmaceuticals proxy fight, then ASCO (American Society of Clinical Oncology), then the Biogen Idec shareholder meeting and then the ADA (American Diabetes Association) meeting all within a week-and-a-half.
It's going to be a crazy busy, stressful couple of weeks. A shareholder meeting, a medical meeting, then another shareholder meeting and finally another medical meeting.
With the latest wave of disclosures hitting the Street, we’re learning about recent moves made by two billionaires. Should you trade in their wake?